Investment Q&A

Q: I'm making a call on this stock to rationalize my portfolio. Do you see any reason to hold this stock in the hope of a reasonable return or is it time to get out at current price and use the $$ for another opportunity.

Q: Good afternoon guys:
I am down a lot on knight and Crh. I will keep Knight but thinking about sucking up my loss with Crh and switch to reliq health. Should I stay put with Crh or switch it out.

Thank you
Mark.

Q: Hi, Don't you guys think there is a huge opportunity cost in owning Knight Therapeutics. Wouldn't it make more sense to buy it when it begins to show some decent momentum?

Q: I own some Zymeworks stock and there was a trading halt for news and then today it dropped $5 despite what I thought was good news, could you comment?

Thanks

Q: Your previous answer - RHT at $1.50 is still expensive, so what would be the reasonable price to get in then? Thanks

Q: SGMO - gene editing, gene therapy, GILD partnership, clinical trials, etc.
CRSP - 0.
Your opinion ? Thanks

Q: I am holding a position in this company waiting to see what the acquisition of Cardiome Pharma will look like - meaning will this put CPH on a path to higher earning. However the stock price is finding new 52 week lows. Would your advice be sell now or give them a quarter or two to see what this acquisition is going to look like?

Q: I hold GILD after averaging down and I am still down I am tempted to switch to Celgene for better recovery opportunity. Please give me your expert opinion.
Raouf

Q: What is your opinion on Align Technologies and Editas? I've read that they are forerunners in their respective fields and although expensive, have high growth potential. What's your analysis?

Q: What top 3-4 marijuana stocks will you recommend?

Q: the stock was down because the FDA placed a hold on its sickle cell drug until some questions are answered. It was down 20% overnight but now down 9%. Is it time to sell?

Q: So now it makes sense why it crashed with no "news" I mean no news for us, but the promoters of the stock, new well in advance of all the inside maneuvers and took their profits , while dumb money are .. well dump money. Pretty much all health care stocks have been a disaster: PHM, CXR, PLI, CRH. The only way to make money on this type of stocks is to be early and leave once everybody is talking about them.

Q: RHT at $1.50 is a good entry price or still expensive.? Thanks

Q: I have a .5% position in this in a cash account. I could use the tax loss, but it seems to recover. Would there be a better place to reinvest, not necessarily the same field.what is your update on this name. I appreciate your advice.
Thank you.

Q: Hi,
Just noticed that TH has issued a Treasury Offering of Convertible Unsecured Senior Notes. The size of the issue is US $ 50 million, par value $100.00. They are 5 Yr cd's witha coupon of 5.75% and a converstion price of US $ 14.75 (equivalent to about Cdn $ 19.12)

Would you feel this is a good value cd, or are we better to just buy the stock directly? As always, we value your opinion.

Thanks,
Dawn

Q: Mr. Hodson, in light of your confidence in GUD, which is now at $8.12, would you advise
loading up on the stock if one can do so right now ? GUD issued stock at $10 in the past, so adding more at this time would seem a good deal. Makes sense, or do you have
reservations in this regard ?

Q: Can you comment on q1 results just released please. What do you think of the stock? Thanks again.

Q: I am considering purchasing this company based on the potential upside. What do you think of this company at this point

Thanks

Q: Hi, I see Vector Vest has Th, rated high on their list. What is your opinion of the stock?

Q: Greetings,
I see you believe ISRG to be one of the best managed companies in the US. I take that as a strong recommendation! Are they managed similar to CSU ie they don’t issue stock and the executives are made to purchase company shares? They appear to have little competition so I conclude they must develop their own technology instead of buying other companies to acquire their technology. How would you asses their growth - is it driven primarily due to organic growth or acquisitions? They appear to have a large cash hoard - are they buying back shares, planning to introduce a dividend or keeping it in reserve for acquisitions? You note growth is likely to be muted for the next 2 to 3 years so, all things being equal, is it reasonable to expect the share price to languish for the next 24 months or so?
Thanks
Jim